Kedar E, Raanan Z, Kafka I, Holland J F, Bekesi G, Weiss D W
J Immunol Methods. 1979;28(3-4):303-19. doi: 10.1016/0022-1759(79)90196-0.
Peripheral blood lymphocytes (PBL) from normal human donors were sensitized in vitro against allogeneic human acute myelocytic leukemia (AML) cells by means of an unidirectional mixed lymphocyte-tumor cell culture (MLTC) technique. The cytotoxic responsiveness of the sensitized lymphocytes, as determined in vitro by the 51Cr-release assay, varied among individual lymphocyte donors and was greatly dependent on the sensitization culture conditions. Induction of cytotoxic effector cells was augmented appreciably by adding to the cultures minute amounts of the immunopotentiating agent MER-BCG. Responding lymphocytes and stimulating leukemia cells cryopreserved for several weeks in liquid nitrogen were as effective as fresh cells in generating effector lymphocytes; the cytotoxic capacity of already sensitized lymphocytes was fully retained by cryopreservation. The implications of these findings for possible clinical employment of in vitro sensitized lymphocytes in adoptive immunotherapy of cancer are discussed.
采用单向混合淋巴细胞 - 肿瘤细胞培养(MLTC)技术,将来自正常人类供体的外周血淋巴细胞(PBL)在体外对同种异体人类急性髓细胞白血病(AML)细胞进行致敏。通过51Cr释放试验在体外测定,致敏淋巴细胞的细胞毒性反应性在个体淋巴细胞供体之间有所不同,并且很大程度上取决于致敏培养条件。通过向培养物中添加微量的免疫增强剂MER - BCG,可明显增强细胞毒性效应细胞的诱导。在液氮中冷冻保存数周的反应性淋巴细胞和刺激性白血病细胞在产生效应淋巴细胞方面与新鲜细胞一样有效;冷冻保存可完全保留已致敏淋巴细胞的细胞毒性能力。讨论了这些发现对于体外致敏淋巴细胞在癌症过继免疫治疗中可能的临床应用的意义。